Search

Your search keyword '"Roldan, I"' showing total 231 results
Start Over Author "Roldan, I"
231 results on '"Roldan, I"'

12. Síncope

Author

Molinero, V. Palazuelos, Giménez, D. Micheloud, González, J.A. Nuevo, and Roldán, I. Muñoz

Published
2015
Full Text
View/download PDF

16. The Role of Mitochondrial Dynamic Dysfunction in Age-Associated Type 2 Diabetes

Author

Vezza T, Díaz-Pozo P, Canet F, de Marañón AM, Abad-Jiménez Z, García-Gargallo C, Roldan I, Solá E, Bañuls C, López-Domènech S, Rocha M, and Víctor VM

Subjects
Aging, Men, Type 2 diabetes, Mitochondria
Abstract

Mitochondrial dynamics, such as fusion and fission, play a critical role in maintaining cellular metabolic homeostasis. The molecular mechanisms underlying these processes include fusion proteins (Mitofusin 1 [MFN1], Mitofusin 2 [MFN2], and optic atrophy 1 [OPA1]) and fission mediators (mitochondrial fission 1 [FIS1] and dynamin-related protein 1 [DRP1]), which interact with each other to ensure mitochondrial quality control. Interestingly, defects in these proteins can lead to the loss of mitochondrial DNA (mtDNA) integrity, impairment of mitochondrial function, a severe alteration of mitochondrial morphology, and eventually cell death. Emerging evidence has revealed a causal relationship between dysregulation of mitochondria dynamics and age-associated type 2 diabetes, a metabolic disease whose rates have reached an alarming epidemic-like level with the majority of cases (59%) recorded in men aged 65 and over. In this sense, fragmentation of mitochondrial networks is often associated with defects in cellular energy production and increased apoptosis, leading, in turn, to excessive reactive oxygen species release, mitochondrial dysfunction, and metabolic alterations, which can ultimately contribute to beta-cell dysfunction and insulin resistance. The present review discusses the processes of mitochondrial fusion and fission and their dysfunction in type 2 diabetes, with special attention given to the therapeutic potential of targeting mitochondrial dynamics in this complex metabolic disorder.

Published
2022

17. Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline

Author

Raghu, G. Remy-Jardin, M. Richeldi, L. Thomson, C.C. Antoniou, K.M. Bissell, B.D. Bouros, D. Buendia-Roldan, I. Caro, F. Crestani, B. Ewing, T. Ghazipura, M. Herman, D.D. Ho, L. Hon, S.M. Hossain, T. Inoue, Y. Johkoh, T. Jones, S. Kheir, F. Khor, Y.H. Knight, S.L. Kreuter, M. Lynch, D.A. Macrea, M. Maher, T.M. Mammen, M.J. Martinez, F.J. Molina-Molina, M. Morisset, J. Myers, J.L. Nicholson, A.G. Olson, A.L. Podolanczuk, A. Poletti, V. Ryerson, C.J. Selman, M. Strek, M.E. Troy, L.K. Wijsenbeek, M. Wilson, K.C. the American Thoracic Society, European Respiratory Society, Japanese Respiratory Society, Asociacion Latinoamericana de Torax

Subjects
respiratory system, respiratory tract diseases
Abstract

Background: This American Thoracic Society, European Respiratory Society, Japanese Respiratory Society, and Asociacion Latinoamericana de Torax guideline updates prior idiopathic pulmonary fibrosis (IPF) guidelines and addresses the progression of pulmonary fibrosis in patients with interstitial lung diseases (ILDs) other than IPF. Methods: A committee was composed of multidisciplinary experts in ILD, methodologists, and patient representatives. 1) Update of IPF: Radiological and histopathological criteria for IPF were updated by consensus. Questions about transbronchial lung cryobiopsy, genomic classifier testing, antacid medication, and antireflux surgery were informed by systematic reviews and answered with evidence-based recommendations using the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) approach. 2) Progressive pulmonary fibrosis (PPF): PPF was defined, and then radiological and physiological criteria for PPF were determined by consensus. Questions about pirfenidone and nintedanib were informed by systematic reviews and answered with evidence-based recommendations using the GRADE approach. Results: 1) Update of IPF: A conditional recommendation was made to regard transbronchial lung cryobiopsy as an acceptable alternative to surgical lung biopsy in centers with appropriate expertise. No recommendation was made for or against genomic classifier testing. Conditional recommendations were made against antacid medication and antireflux surgery for the treatment of IPF. 2) PPF: PPF was defined as at least two of three criteria (worsening symptoms, radiological progression, and physiological progression) occurring within the past year with no alternative explanation in a patient with an ILD other than IPF. A conditional recommendation was made for nintedanib, and additional research into pirfenidone was recommended. Conclusions: The conditional recommendations in this guideline are intended to provide the basis for rational, informed decisions by clinicians. © 2022 by the American Thoracic Society

Published
2022

24. [Impact of antithrombotic treatment and geriatric syndromes in octogenarians with atrial fibrillation and ischaemic heart disease. Atrial Fibrillation and Ischemic Heart Disease in the Elderly]

Author

Bonanad Lozano C, Diez-Villanueva P, Blas S, Ayesta A, Ibars S, Ariza-Sole A, Ferreiro J, Moreno R, Roldan I, Marin F, Carol Ruiz A, Garcia Pardo H, Sanchis J, Cruz-Gonzalez I, Anguita M, Cequier A, Ruiz Garcia J, and Martinez-Selles M

Abstract

BACKGROUND AND OBJECTIVES: The prevalence of atrial fibrillation (AF) and ischaemic heart disease (IHC) increases with age. They coexist in up to 20% of octogenarian patients, a situation that poses a therapeutic challenge. Trials that have addressed this scenario, which included a low percentage of octogenarians, showed that double therapy (single antiplatelet+anticoagulation) compared to triple therapy (double antiplatelet+anticoagulation) was associated with less bleeding events, especially with direct oral anticoagulants. These studies did not have sufficient power to detect differences in ischaemic events. On the other hand, prevalent characteristics in the elderly, such as geriatric syndromes, were not assessed in these studies, and are not usually evaluated in clinical practice. Accordingly, their prognostic impact remains unknown in this clinical context. METHODS: Observational, prospective, and multicentre study that will include patients =80 years with AF and IHC in Spain. Baseline characteristics and geriatric syndromes will be assessed, as well as the choice of antithrombotic treatment. The primary endpoint is cardiovascular and overall mortality at one and three years follow-up. RESULTS: This study will assess both characteristics and prognosis of octogenarian patients with AF and IHC in Spain, the factors involved in the choice of antithrombotic treatment, and the incidence of ischaemic and haemorrhagic events during the short- and long-term follow-up. CONCLUSION: This study will contribute to improve the knowledge in terms of safety and efficacy of the different therapeutic options in older patients with AF and IHC, as well as their prognostic impact.

Published
2020

25. Recommendations on antithrombotic treatment during the COVID-19 pandemic. Position statement of the Working Group on Cardiovascular Thrombosis of the Spanish Society of Cardiology

Author

Vivas D, Roldan V, Esteve-Pastor M, Roldan I, Tello-Montoliu A, Ruiz-Nodar J, Cosin-Sales J, Gamez J, Consuegra L, Ferreiro J, Marin F, Arrarte V, Anguita M, Cequier A, and Perez-Villacastin J

Subjects
Coronavirus, SARS-CoV-2, Antithrombotics, COVID-19, Thrombosis
Abstract

The new coronavirus SARS-CoV-2, which gives rise to the highly contagious COVID-19 disease, has caused a pandemic that is overwhelming health care systems worldwide. Affected patients have been reported to have a heightened inflammatory state that increases their thrombotic risk. However, there is very scarce information on the management of thrombotic risk, coagulation disorders, and anticoagulant therapy. In addition, the situation has also greatly influenced usual care in patients not infected with COVID-19. This article by the Working Group on Cardiovascular Thrombosis of the Spanish Society of Cardiology aims to summarize the available information and to provide a practical approach to the management of antithrombotic therapy. (C) 2020 Sociedad Espanola de Cardiologia. Published by Elsevier Espana, S.L.U. All rights reserved.

Published
2020

26. Is “one size fits all” anti-aggregation really effective? Variability in the response to P2Y12 receptor inhibitors in obese patients

Author

Playan Escribano, J, primary, Vivas Balcones, D, additional, Lugo Gavidia, L.M, additional, Gomez Polo, J.C, additional, Marcano Fernandez, A.L, additional, Bernardo, E, additional, Ortega, M.A, additional, De La Hera Galarza, J.M, additional, Tello-Montoliu, A, additional, Besteiro Vazquez, A, additional, Silva, I, additional, Marin, F, additional, Roldan, I, additional, Gomez-Hospital, J.A, additional, and Ferreiro, J.L, additional

Published
2020
Full Text
View/download PDF

33. OP0036 METHOTREXATE AND RHEUMATOID ARTHRITIS ASSOCIATED INTERSTITIAL LUNG DISEASE

Author

Juge, P. A., primary, Lee, J. S., additional, Lau, J., additional, Kawano, L., additional, Rojas-Serrano, J., additional, Sebastiani, M., additional, Koduri, G., additional, Matteson, E., additional, Bonfiglioli, K., additional, Sawamura, M., additional, Kairalla, R., additional, Cavagna, L., additional, Bozzalla Cassione, E., additional, Manfredi, A., additional, Mejia, M., additional, Rodríguez Henríquez, P., additional, Gonzalez-Perez, M. I., additional, Falfan-Valencia, R., additional, Buendia-Roldan, I., additional, Perez-Rubio, G., additional, Ebstein, E., additional, Gazal, S., additional, Borie, R., additional, Ottaviani, S., additional, Kannengiesser, C., additional, Wallaert, B., additional, Uzunhan, Y., additional, Nunes, H., additional, Valeyre, D., additional, Saidenberg Kermanac’h, N., additional, Boissier, M. C., additional, Wemeau Stervinou, L., additional, Flipo, R. M., additional, Marchand-Adam, S., additional, Richette, P., additional, Allanore, Y., additional, Dromer, C., additional, Truchetet, M. E., additional, Richez, C., additional, Schaeverbeke, T., additional, Lioté, H., additional, Thabut, G., additional, Deane, K., additional, Solomon, J., additional, Doyle, T., additional, Ryu, J. H., additional, Rosas, I. O., additional, Holers, V. M., additional, Boileau, C., additional, Debray, M. P., additional, Porcher, R., additional, Schwartz, D. A., additional, Vassallo, R., additional, Crestani, B., additional, and Dieudé, P., additional

Published
2020
Full Text
View/download PDF

34. P882 Heart murmur in a 74-year-old patient with a Dacron aortic graft admitted for sepsis after a laparoscopic left colectomy

Author

Romero Dorta, E, primary, Fernandez Galera, R, additional, Roldan, I, additional, Vizuete, J, additional, Martin, G, additional, Orozco, J, additional, Hornero, F, additional, Bertolin, J, additional, Faga, V, additional, Perez-Gil, M M, additional, Serrats, R, additional, Callizo, R, additional, Cuevas, A, additional, Sorribes, A, additional, and Mora, V, additional

Published
2020
Full Text
View/download PDF

36. 255Impact of the type of acute coronary syndrome on the pharmocodynamic response to P2Y12 inhibitors in the acute and maintenance phase of therapy

Author

Lugo Gavidia, L, primary, Vivas, D, additional, De La Hera, J M, additional, Tello-Montoliu, A, additional, Marcano, A L, additional, Besteiro, A, additional, Silva, I, additional, Gomez-Polo, J C, additional, Playan, J, additional, Gomez-Hospital, J A, additional, Cequier, A, additional, Marin, F, additional, Roldan, I, additional, and Ferreiro, J L, additional

Published
2019
Full Text
View/download PDF

37. Global Review of the Age Distribution of Rotavirus Disease in Children Aged <5 Years Before the Introduction of Rotavirus Vaccination

Author

Hasso-Agopsowicz, Mateusz, Ladva, Nanji, Lopman, Benjamin, Sanderson, Colin, Cohen, Adam, Tate, Jacqueline, Riveros, Ximena, Henao-Restrepo, Ana Maria, Clark, Andrew E., Ladva, Chandresh Nanji, Alkorta, M, Atchison, C, Banajeh, S, Becker-Dreps, S, Benhafid, M, Bhandari, N, Bodhidatta, L, Braeckman, T, Bwogi, J, de Cassia Compagnoli Carmona, R, Cilla, G., Contreras-Roldan, I, Coulson, B, Cunliffe, N, Dagan, R, Givon, N, Degiuseppe, J, Dhiman, S, Dian, Z, Díaz, J., Dutta, S, Krishnan, T, Manna, B, Fletcher-Lartey, S, Fu, C, Gendrel, D., Ghenghesh, K., Gonzalez Mago, G, De Grazia, S, Grimwood, K, Groome, M, Haque, A., Heininger, U, Houpt, E, Iturriza-Gómara, M., Hungerford, D, Jarquin, C, McCracken, J, Contreras, I, Cordon-Rosales, C, Kaiser-Labusch, P, Kang, G, Kar, S, Kiulia, N, Kotloff, K, Latipov, R, Linhares, A, Lorrot, M., Mandile, M, Mast, C, Mathew, M., Matinon-Torres, F, Matthijnssens, J, Mladenova, Z., Monini, M, Montes, M, Arana, A, Motamedifar, M, Najafi, A, Nelson, T., Nokes, J, Ntoumi, F, Numazaki, K, O’Reilly, C, Ochoa, T, Page, N, Page, A., Langendorf, C, Podkolzin, A, Quach, C, Racz, M, de Rougemont, Alexis, Ruiz-Palacios, G, Saha, S, Satter, S, Soares, L, Sudarmo, S, Shigemura, K, Shirakawa, T, Athiyyah, A, Tagbo, B, Tarr, P, Klein, E., Denno, D, Turner, A., Uzoma, E, Vatosoa, R, Wandera, E, Wikswo, M, Payne, D, Yhu-Chering, H, Yoshikawa, T, Sugata, K, Yuan, Q, Liying, L, Zaman, K., Zhou, X -N, Zhang, S -X, Xu, Wei-Jiang, Serhan, Fatima, Nakamura, Tomoka, Antoni, Sébastien, Agócs, Mary, Murray, Jillian, Cherian, Thomas, Mwenda, Jason, Weldegebriel, Goitom, Biey, Joseph, Cheikh, Dah, Teleb, Nadia, Rahman, Hossam Abdel, Ahmed, Hinda, Daniels, Danni, Videbaek, Dovile, Wasley, Annemarie, Singh, Simarjit, de Oliveira, Lucia, Rey-Benito, Gloria, Sanwogou, N Jennifer, Liyanage, Jayantha, Wijesinghe, Pushpa Ranjan, Batmunkh, Nyambat, Grabovac, Varja, Fox, Kimberley, Paladin, Fem Julia, Henschke, Nicholas, Queensland University of Technology [Brisbane] (QUT), Microbiology Service, Hospital Donostia, Grupo de Investigación en Energía y Medioambiente [Bucaramanga]] (GIEMA), Universidad Industrial de Santander [Bucaramanga] (UIS), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), University of Tripoli - University Al Fateh, Visva Bharati University, Enteric Virus Unit, Virus Reference Department, Centre for Infections, Health Protection Agency, Department of Virology, National Reference Laboratory of Enteroviruses, National Center of Infectious and Parasitic Diseases [Sofia, Bulgarie] (NCIPD), Friction Stir Laboratory, Brigham Young University (BYU), UFR des Sciences de Santé (Université de Bourgogne), Université de Bourgogne (UB), Centre National de Référence des virus entériques [CHU de Dijon] (CNR virus entériques), Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), Laboratoire de sérologie-virologie (CHU de Dijon), Procédés Alimentaires et Microbiologiques [Dijon] (PAM), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université de Bourgogne (UB)-AgroSup Dijon - Institut National Supérieur des Sciences Agronomiques, de l'Alimentation et de l'Environnement, Institut de biologie moléculaire des plantes (IBMP), Centre National de la Recherche Scientifique (CNRS)-Université de Strasbourg (UNISTRA), School of Social and Community Medicine [Bristol], University of Bristol [Bristol], Vaccine Preventable Disease and Immunization, Organisation Mondiale de la Santé / World Health Organization Office (OMS / WHO), and University of Stavanger

Subjects
rotavirus gastroenteritis, age distribution, rotavirus, [SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases, vaccine, [SDV.MP.VIR]Life Sciences [q-bio]/Microbiology and Parasitology/Virology
Abstract

International audience; We sought datasets with granular age distributions of rotavirus-positive disease presentations among children

Published
2019

39. Relationship between Oxidative Stress, ER Stress, and Inflammation in Type 2 Diabetes: The Battle Continues

Author

Burgos-Morón E, Abad-Jiménez Z, Marañón AM, Iannantuoni F, Escribano-López I, López-Domènech S, Salom C, Jover A, Mora V, Roldan I, Solá E, Rocha M, and Víctor VM

Abstract

Type 2 diabetes (T2D) is a metabolic disorder characterized by hyperglycemia and insulin resistance in which oxidative stress is thought to be a primary cause. Considering that mitochondria are the main source of ROS, we have set out to provide a general overview on how oxidative stress is generated and related to T2D. Enhanced generation of reactive oxygen species (ROS) and oxidative stress occurs in mitochondria as a consequence of an overload of glucose and oxidative phosphorylation. Endoplasmic reticulum (ER) stress plays an important role in oxidative stress, as it is also a source of ROS. The tight interconnection between both organelles through mitochondrial-associated membranes (MAMs) means that the ROS generated in mitochondria promote ER stress. Therefore, a state of stress and mitochondrial dysfunction are consequences of this vicious cycle. The implication of mitochondria in insulin release and the exposure of pancreatic beta-cells to hyperglycemia make them especially susceptible to oxidative stress and mitochondrial dysfunction. In fact, crosstalk between both mechanisms is related with alterations in glucose homeostasis and can lead to the diabetes-associated insulin-resistance status. In the present review, we discuss the current knowledge of the relationship between oxidative stress, mitochondria, ER stress, inflammation, and lipotoxicity in T2D.

Published
2019

42. Perioperative and Periprocedural Management of Antithrombotic Therapy: Consensus Document of SEC, SEDAR, SEACV, SECTCV, AEC, SECPRE, SEPD, SEGO, SEHH, SETH, SEMERGEN, SEMFYC, SEMG, SEMICYUC, SEMI, SEMES, SEPAR, SENEC, SEO, SEPA, SERVE', SECOT and AEU

Author

Vivas, D, Roldan, I, Ferrandis, R, Marin, F, Roldan, V, Tello-Montoliu, A, Ruiz J, Jose Gomez-Doblas, J, Martin, A, Vicente Llau, J, Jose Ramos-Gallo, M, Munoz, R, Ignacio Arcelus, J, Leyva, F, Alberca, F, Oliva, R, Maria Gomez, A, Montero, C, Arikans, F, Ley, L, Santos-Buesou, E, Figuero, E, Bujaldon, A, Urbane, J, Otero, R, Francisco Hermida, J, Egocheaga, I, Luis Llisterri, J, Maria Lobos, J, Serrano, A, Madridano, O, Luis Ferreiro, J, Cassinello, C, Gomez-Luque, A, Hidalgo, F, Sierra, P, Marco P, Mateo Arranza, J, Palomo, V, Guerrero, A, Anguita, M, and Iniguez, A

Subjects
Anticoagulation, Antithrombotic, Antiplatelet, Surgery
Abstract

During the last few years, the number of patients receiving anticoagulant and antiplatelet therapy has increased worldwide. Since this is a chronic treatment, patients receiving it can be expected to need some kind of surgery or intervention during their lifetime that may require treatment discontinuation. The decision to withdraw antithrombotic therapy depends on the patient's thrombotic risk versus hemorrhagic risk. Assessment of both factors will show the precise management of anticoagulant and antiplatelet therapy in these scenarios. The aim of this consensus document, coordinated by the Cardiovascular Thrombosis Working Group of the Spanish Society of Cardiology, and endorsed by most of the Spanish scientific societies of clinical specialities that may play a role in the patient-health care process during the perioperative or periprocedural period, is to recommend some simple and practical guidelines with a view to homogenizing daily clinical practice. Full English text available from: www.revespcardiol.org/en (C) 2018 Sociedad Espafiola de Cardiologia. Published by Elsevier Espania, S.L.U. All rights reserved.

Published
2018

43. MUC5B PROMOTER VARIANT RS35705950 IS A RISK FACTOR FOR RHEUMATOID ARTHRITIS - INTERSTITIAL LUNG DISEASE

Author

Juge, P. -A. Lee, J. S. Ebstein, E. Furukawa, H. and Dobrinskikh, E. Gazal, S. Kannengiesser, C. Ottaviani, S. and Tsuchiya, N. Oka, S. Tohma, S. Rojas-Serrano, J. and Gonzalez-Perez, M. -I. Mejia, M. Buendia-Roldan, I. and Falfan-Valencia, R. Manali, E. Papiris, S. A. Karageorgas, T. Boumpas, D. Antoniou, K. Van Moorsel, C. van der Vis, J. de Man, Y. Grutters, J. Wang, Y. Borie, R. and Wemeau-Stervinou, L. Wallaert, B. Flipo, R. -M. Nunes, H. and Valeyre, D. Saidenberg, N. Marchand-Adam, S. Deane, K. and Walts, A. Fingerlin, T. Matteson, E. Niewold, T. and Assayag, D. Gross, A. Wolters, P. Schwarz, M. Holers, M. and Solomon, J. Doyle, T. Debray, M. -P. Boileau, C. and Crestani, B. Schwartz, D. Dieude, P.

Published
2018

49. OP0284 Muc5b promoter variant rs35705950 is a risk factor for rheumatoid arthritis – interstitial lung disease

Author

Juge, P.-A., primary, Lee, J.S., additional, Ebstein, E., additional, Furukawa, H., additional, Dobrinskikh, E., additional, Gazal, S., additional, Kannengiesser, C., additional, Ottaviani, S., additional, Tsuchiya, N., additional, Oka, S., additional, Tohma, S., additional, Rojas-Serrano, J., additional, Gonzalez-Perez, M.-I., additional, Mejia, M., additional, Buendia-Roldan, I., additional, Falfan-Valencia, R., additional, Manali, E., additional, Papiris, S.A., additional, Karageorgas, T., additional, Boumpas, D., additional, Antoniou, K., additional, Van Moorsel, C., additional, van der Vis, J., additional, de Man, Y., additional, Grutters, J., additional, Wang, Y., additional, Borie, R., additional, Wemeau-Stervinou, L., additional, Wallaert, B., additional, Flipo, R.-M., additional, Nunes, H., additional, Valeyre, D., additional, Saidenberg, N., additional, Marchand-Adam, S., additional, Deane, K., additional, Walts, A., additional, Fingerlin, T., additional, Matteson, E., additional, Niewold, T., additional, Assayag, D., additional, Gross, A., additional, Wolters, P., additional, Schwarz, M., additional, Holers, M., additional, Solomon, J., additional, Doyle, T., additional, Debray, M.-P., additional, Boileau, C., additional, Crestani, B., additional, Schwartz, D., additional, and Dieudé, P., additional

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results